1
|
Chada RR, Kajare RC, Bhandari MC, Mohammed SZ, Khatravath M, Warudikar K, Punna N. Facile access to [1,2]-oxazine derivatives via annulations of aminoxy-tethered 1,7-enynes. Org Biomol Chem 2021; 19:809-821. [PMID: 33403372 DOI: 10.1039/d0ob02279a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
An efficient approach for the highly diastereoselective construction of functionalized cyclopenta[d][1,2]oxazines via sequential oxyamination and Pauson-Khand reaction of readily accessible propargylic alcohols has been developed. Furthermore, the ring closing metathesis of these N-O linked 1,7-enynes afforded vinylated-[1,2]oxazines in good yields. The reduction of the N-O bond of the obtained cyclopenta[d][1,2]oxazine is accomplished to access cyclopentenone-based amino alcohols.
Collapse
Affiliation(s)
- Raji Reddy Chada
- Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500007, India. and Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, India
| | - Roshan Chandrakant Kajare
- Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500007, India. and Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, India
| | - Mayur C Bhandari
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, India
| | - Siddique Z Mohammed
- Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500007, India. and Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, India
| | - Mahender Khatravath
- Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500007, India.
| | - Kamalkishor Warudikar
- Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500007, India. and Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, India
| | - Nagender Punna
- Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500007, India. and Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, India
| |
Collapse
|
2
|
The main directions and recent trends in the synthesis and use of isoxazoles. Chem Heterocycl Compd (N Y) 2020. [DOI: 10.1007/s10593-020-02718-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
3
|
Välimäki MJ, Tölli MA, Kinnunen SM, Aro J, Serpi R, Pohjolainen L, Talman V, Poso A, Ruskoaho HJ. Discovery of Small Molecules Targeting the Synergy of Cardiac Transcription Factors GATA4 and NKX2-5. J Med Chem 2017; 60:7781-7798. [PMID: 28858485 DOI: 10.1021/acs.jmedchem.7b00816] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Transcription factors are pivotal regulators of gene transcription, and many diseases are associated with the deregulation of transcriptional networks. In the heart, the transcription factors GATA4 and NKX2-5 are required for cardiogenesis. GATA4 and NKX2-5 interact physically, and the activation of GATA4, in cooperation with NKX2-5, is essential for stretch-induced cardiomyocyte hypertrophy. Here, we report the identification of four small molecule families that either inhibit or enhance the GATA4-NKX2-5 transcriptional synergy. A fragment-based screening, reporter gene assay, and pharmacophore search were utilized for the small molecule screening, identification, and optimization. The compounds modulated the hypertrophic agonist-induced cardiac gene expression. The most potent hit compound, N-[4-(diethylamino)phenyl]-5-methyl-3-phenylisoxazole-4-carboxamide (3, IC50 = 3 μM), exhibited no activity on the protein kinases involved in the regulation of GATA4 phosphorylation. The identified and chemically and biologically characterized active compound, and its derivatives may provide a novel class of small molecules for modulating heart regeneration.
Collapse
Affiliation(s)
- Mika J Välimäki
- Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki , Helsinki FI-00014, Finland.,Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu , Oulu FI-90014, Finland
| | - Marja A Tölli
- Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu , Oulu FI-90014, Finland
| | - Sini M Kinnunen
- Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki , Helsinki FI-00014, Finland.,Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu , Oulu FI-90014, Finland
| | - Jani Aro
- Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu , Oulu FI-90014, Finland
| | - Raisa Serpi
- Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu , Oulu FI-90014, Finland
| | - Lotta Pohjolainen
- Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki , Helsinki FI-00014, Finland
| | - Virpi Talman
- Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki , Helsinki FI-00014, Finland
| | - Antti Poso
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland , Kuopio FI-70211, Finland
| | - Heikki J Ruskoaho
- Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki , Helsinki FI-00014, Finland.,Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu , Oulu FI-90014, Finland
| |
Collapse
|
4
|
Shao D, Yang Y, Xue F, Luo X, Wubulikasimu R, Li Y, Gao R, Ye W. Design, Synthesis and Inhibitory Properties against Coxsackie B3/B6 of Some Novel Triazole Derivatives. ACTA ACUST UNITED AC 2013. [DOI: 10.4236/ijoc.2013.31a005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
5
|
Mirzaei YR, Weaver MJ, Steiger SA, Kearns AK, Gajewski MP, Rider KC, Beall HD, Natale NR. Improved synthesis of 3-aryl isoxazoles containing fused aromatic rings. Tetrahedron 2012; 68:10360-10364. [PMID: 23526841 DOI: 10.1016/j.tet.2012.09.084] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A critical comparison of methods to prepare sterically hindered 3-aryl isoxazoles containing fused aromatic rings using the nitrile oxide cycloaddition (NOC) reveal that modification of the method of Bode, Hachisu, Matsuura, and Suzuki (BHMS), utilizing either triethylamine as base or sodium enolates of the diketone, ketoester, and ketoamide dipolarophiles, respectively, was the method of choice for this transformation.
Collapse
Affiliation(s)
- Yousef R Mirzaei
- Medicinal Chemistry Graduate Program, Department of Biomedical and Pharmaceutical Sciences, The University of Montana, Missoula, MT 59812, USA
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Rediger A, Piechowski CL, Habegger K, Grüters A, Krude H, Tschöp MH, Kleinau G, Biebermann H. MC4R dimerization in the paraventricular nucleus and GHSR/MC3R heterodimerization in the arcuate nucleus: is there relevance for body weight regulation? Neuroendocrinology 2012; 95:277-88. [PMID: 22327910 DOI: 10.1159/000334903] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2011] [Accepted: 11/06/2011] [Indexed: 01/21/2023]
Abstract
The worldwide obesity epidemic is increasing, yet at this time, no long-acting and specific pharmaceutical therapies are available. Peripheral hormonal signals communicate metabolic status to the hypothalamus by activating their corresponding receptors in the arcuate nucleus (ARC). In this brain region, a variety of G protein-coupled receptors (GPCRs) are expressed that are potentially involved in weight regulation, but so far, the detailed function of most hypothalamic GPCRs is only partially understood. An important and underappreciated feature of GPCRs is the capacity for regulation via di- and heterodimerization. Increasing evidence implicates that heterodimerization of GPCRs results in profound functional consequences. Recently, we could demonstrate that interaction of the melanocortin 3 receptor (MC3R) and the growth hormone secretagogue receptor (GHSR)-1a results in a modulation of function in both receptors. Although the physiological role of GPCR-GPCR interaction in the hypothalamus is yet to be elucidated, this concept promises new avenues for investigation and understanding of hypothalamic functions dependent on GPCR signaling. Since GPCRs are important targets for drugs to combat many diseases, identification of heterodimers may be a prerequisite for highly specific drugs. Therefore, a detailed understanding of the mechanisms and their involvement in weight regulation is necessary. Fundamental to this understanding is the interplay of GPCR-GPCR in the hypothalamic nuclei in energy metabolism. In this review, we summarize the current knowledge on melanocortin receptors and GHSR-1a in hypothalamic weight regulation, especially as they pertain to possible drug targets. Furthermore, we include available evidence for the participation and significance of GPCR dimerization.
Collapse
MESH Headings
- Animals
- Appetite Regulation/physiology
- Arcuate Nucleus of Hypothalamus/anatomy & histology
- Arcuate Nucleus of Hypothalamus/metabolism
- Arcuate Nucleus of Hypothalamus/physiology
- Body Weight/physiology
- Humans
- Models, Biological
- Paraventricular Hypothalamic Nucleus/anatomy & histology
- Paraventricular Hypothalamic Nucleus/metabolism
- Paraventricular Hypothalamic Nucleus/physiology
- Protein Multimerization/physiology
- Receptor, Melanocortin, Type 3/metabolism
- Receptor, Melanocortin, Type 3/physiology
- Receptor, Melanocortin, Type 4/metabolism
- Receptor, Melanocortin, Type 4/physiology
- Receptors, Ghrelin/metabolism
- Receptors, Ghrelin/physiology
Collapse
Affiliation(s)
- Anne Rediger
- Institute of Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin, Humboldt University, Berlin, Germany
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Yu M, Lizarzaburu M, Beckmann H, Connors R, Dai K, Haller K, Li C, Liang L, Lindstrom M, Ma J, Motani A, Wanska M, Zhang A, Li L, Medina JC. Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity. Bioorg Med Chem Lett 2010; 20:1758-62. [DOI: 10.1016/j.bmcl.2010.01.043] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2009] [Revised: 01/05/2010] [Accepted: 01/06/2010] [Indexed: 01/21/2023]
|
8
|
Chollet C, Meyer K, Beck-Sickinger AG. Ghrelin-a novel generation of anti-obesity drug: design, pharmacomodulation and biological activity of ghrelin analogues. J Pept Sci 2009; 15:711-30. [DOI: 10.1002/psc.1177] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
9
|
Sharma S, Sharma BK, Pilania P, Singh P, Prabhakar YS. Modeling of the growth hormone secretagogue receptor antagonistic activity using chemometric tools. J Enzyme Inhib Med Chem 2009; 24:1024-33. [PMID: 19548781 DOI: 10.1080/14756360802608054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
A quantitative structure-activity relationship (QSAR) study has been carried out on growth hormone secretagogue receptor antagonistic activity of the derivatives of 2,4-diaminopyrimidine. To obtain significant QSARs, the approaches involving the non-parametric such as Fujita-Ban, and the parametric based on physicochemical and DRAGON descriptors in Hansch type of analysis have been employed. The Fujita-Ban approach, however, was constrained to 18 compounds only due to a limited number of substituents appeared at varying positions. The derived contributions of different substituents and the parent moiety were used to identify the potential congeners. The physicochemical model of Hansch was subsequently used to interpret the type of interactions involved between the receptor sites and varying positions of these compounds. The study, employing DRAGON descriptors in Hansch approach was also carried out on this data set to discuss the prevailing interactions in terms of topological descriptors. The derived highest significant model was discussed to delineate the type of interactions involved and suggestions have been made for different alterations to lead to further potential compounds of the series.
Collapse
Affiliation(s)
- Susheela Sharma
- Department of Engineering Chemistry, Sobhasaria Engineering College, Sikar 332 021, India
| | | | | | | | | |
Collapse
|
10
|
Abstract
Background: Ghrelin is a peptide produced predominantly in the stomach and intestines, and is a natural growth hormone (GH) secretagogue-receptor ligand. It is able to stimulate GH release, but it also exhibits an important role in conditions related to processes regulating nutrition, body composition and growth, and heart, liver, thyroid or kidney dysfunction. Drug discovery efforts initially focused on ghrelin-receptor agonists, known as GH secretagogues, to be used as anabolic agents, but none of them reached the market. Discussion: The latest developments in this field are constituted by the discovery of new nonpeptidic compounds endowed with interesting properties: oxindole agonists are able to exert an increase in the fat-free mass, while ghrelin was reported to increase the fat mass gain, and triazole- and 2,4-diaminopyrimidine-based antagonists were shown to be able to reduce food intake, without inhibition of GH secretion stimulated by an agonist to the ghrelin receptor. Other antagonist compounds (quinazolinones) were discovered as antiobesity/antidiabetic agents. Moreover, inverse agonists have been discovered that are able to reduce weight gain. Conclusions: Taking into account the great number of pathological conditions related to ghrelin, and the discovery of several compounds able to modulate the ghrelin receptor, its importance in the field of medicinal chemistry research is set to increase significantly.
Collapse
|
11
|
Tao YX. Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol Ther 2008; 120:129-48. [PMID: 18768149 DOI: 10.1016/j.pharmthera.2008.07.005] [Citation(s) in RCA: 126] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2008] [Accepted: 07/22/2008] [Indexed: 01/17/2023]
Abstract
The existence of constitutive activity for G protein-coupled receptors (GPCRs) was first described in 1980s. In 1991, the first naturally occurring constitutively active mutations in GPCRs that cause diseases were reported in rhodopsin. Since then, numerous constitutively active mutations that cause human diseases were reported in several additional receptors. More recently, loss of constitutive activity was postulated to also cause diseases. Animal models expressing some of these mutants confirmed the roles of these mutations in the pathogenesis of the diseases. Detailed functional studies of these naturally occurring mutations, combined with homology modeling using rhodopsin crystal structure as the template, lead to important insights into the mechanism of activation in the absence of crystal structure of GPCRs in active state. Search for inverse agonists on these receptors will be critical for correcting the diseases cause by activating mutations in GPCRs. Theoretically, these inverse agonists are better therapeutics than neutral antagonists in treating genetic diseases caused by constitutively activating mutations in GPCRs.
Collapse
Affiliation(s)
- Ya-Xiong Tao
- Department of Anatomy, Physiology and Pharmacology, 212 Greene Hall, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
| |
Collapse
|
12
|
Bossola M, Pacelli F, Doglietto GB. Cancer cachexia: drugs in the patent literature. Expert Opin Ther Pat 2008. [DOI: 10.1517/13543776.18.7.739] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
13
|
Abstract
The 28-amino acid peptide ghrelin is a neuroendocrine hormone synthesized primarily in the stomach. It stimulates growth hormone secretion and appetite, thus promoting food intake and body-weight gain. The pharmacological properties of this peptide are mediated by the growth hormone secretagogue receptor type 1a (GHS-R1a). Given its wide spectrum of biological activities, it is evident that the discovery of ghrelin and its receptor has opened up many perspectives in the fields of neuroendocrine and metabolic research and has had an influence on such fields of internal medicine as gastroenterology, oncology, and cardiology. It is therefore increasingly likely that synthetic, peptidyl, and nonpeptidyl GHS-R1a ligands, acting as agonists, partial agonists, antagonists, or inverse agonists, could have both clinical and therapeutic potential. This review summarizes the various types of GHS-R1a ligands that have been described in the literature and discusses the recent progress made in this research area.
Collapse
Affiliation(s)
- Aline Moulin
- Institut des Biomolécules Max Mousseron, Faculté de Pharmacie, 15 avenue Charles Flahault, BP 1441, 34093 Montpellier Cedex, France
| | | | | | | |
Collapse
|
14
|
Blakeney JS, Reid RC, Le GT, Fairlie DP. Nonpeptidic Ligands for Peptide-Activated G Protein-Coupled Receptors. Chem Rev 2007; 107:2960-3041. [PMID: 17622179 DOI: 10.1021/cr050984g] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jade S Blakeney
- Centre for Drug Design and Development, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | | |
Collapse
|
15
|
Muccioli G, Baragli A, Granata R, Papotti M, Ghigo E. Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology 2007; 86:147-64. [PMID: 17622734 DOI: 10.1159/000105141] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2007] [Accepted: 05/21/2007] [Indexed: 12/23/2022]
Abstract
Ghrelin is a gastric polypeptide displaying strong GH-releasing activity by activation of the type 1a GH secretagogue receptor (GHS-R1a) located in the hypothalamus-pituitary axis. GHS-R1a is a G-protein-coupled receptor that, upon the binding of ghrelin or synthetic peptidyl and non-peptidyl ghrelin-mimetic agents known as GHS, preferentially couples to G(q), ultimately leading to increased intracellular calcium content. Beside the potent GH-releasing action, ghrelin and GHS influence food intake, gut motility, sleep, memory and behavior, glucose and lipid metabolism, cardiovascular performances, cell proliferation, immunological responses and reproduction. A growing body of evidence suggests that the cloned GHS-R1a alone cannot be the responsible for all these effects. The cloned GHS-R1b splice variant is apparently non-ghrelin/GHS-responsive, despite demonstration of expression in neoplastic tissues responsive to ghrelin not expressing GHS-R1a; GHS-R1a homologues sensitive to ghrelin are capable of interaction with GHS-R1b, forming heterodimeric species. Furthermore, GHS-R1a-deficient mice do not show evident abnormalities in growth and diet-induced obesity, suggesting the involvement of another receptor. Additional evidence of the existence of another receptor is that ghrelin and GHS do not always share the same biological activities and activate a variety of intracellular signalling systems besides G(q). The biological actions on the heart, adipose tissue, pancreas, cancer cells and brain shared by ghrelin and the non-acylated form of ghrelin (des-octanoyl ghrelin), which does not bind GHS-R1a, represent the best evidence for the existence of a still unknown, functionally active binding site for this family of molecules. Finally, located in the heart and blood vessels is the scavenger receptor CD36, involved in the endocytosis of the pro-atherogenic oxidized low-density lipoproteins, which is a pharmacologically and structurally distinct receptor for peptidyl GHS and not for ghrelin. This review highlights the most recently discovered features of GHS-R1a and the emerging evidence for a novel group of receptors that are not of the GHS1a type; these appear involved in the transduction of the multiple levels of information provided by GHS and ghrelin.
Collapse
Affiliation(s)
- Giampiero Muccioli
- Division of Pharmacology, Department of Anatomy, Pharmacology and Forensic Medicine, University of Turin, Turin, Italy
| | | | | | | | | |
Collapse
|
16
|
Liu B, Liu M, Xin Z, Zhao H, Serby MD, Kosogof C, Nelson LTJ, Szczepankiewicz BG, Kaszubska W, Schaefer VG, Falls HD, Lin CW, Collins CA, Sham HL, Liu G. Optimization of 2,4-diaminopyrimidines as GHS-R antagonists: Side chain exploration. Bioorg Med Chem Lett 2006; 16:1864-8. [PMID: 16442284 DOI: 10.1016/j.bmcl.2006.01.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2005] [Revised: 12/27/2005] [Accepted: 01/04/2006] [Indexed: 11/23/2022]
Abstract
The synthesis and structure-activity relationships of the 4- and 6-substituents of 2,4-diaminopyrimidine-based growth hormone secretagogue receptor (GHS-R) antagonists are described. Diaminopyrimidines with 6-norbornenyl (4n) and 6-tetrahydrofuranyl (4p) substitutents were found to exhibit potent GHS-R antagonism and good selectivity (approximately 1000-fold) against dihydrofolate reductase.
Collapse
Affiliation(s)
- Bo Liu
- Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6098, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Centrally Acting Anti-Obesity Agents. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2006. [DOI: 10.1016/s0065-7743(06)41005-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|
18
|
Zhao H. Growth hormone secretagogue receptor antagonists as potential therapeutic agents for obesity. Drug Dev Res 2005. [DOI: 10.1002/ddr.20011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|